Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Histone deacetylase 1, 2, 3, and 10 are members of the histone deacetylase enzyme family, which remove acetyl groups from lysine residues on histone proteins, leading to chromatin condensation and transcriptional repression. These enzymes play critical roles in regulating gene expression, cell cycle progression, apoptosis, and development. Aberrant function of these enzymes contributes to the pathogenesis of diseases such as cancer, neurodegeneration, and inflammatory disorders. Therapeutic inhibitors targeting HDACs, particularly class I (HDAC1, HDAC2, HDAC3) and class IIb (HDAC10), are used in cancer treatment and are under investigation for other diseases. Each isoform has unique biological and pathological roles, necessitating specific characterization and targeting for therapeutic purposes.
Inhibition of deacetylase activity, resulting in hyperacetylation of histones and transcriptional activation of silenced genes (leading to cell cycle arrest/differentiation/apoptosis in tumor cells); Modulation of acetylation state on non-histone proteins affecting cell growth, survival, and apoptosis
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Histone deacetylase 1, 2, 3, and 10 (HDAC1, HDAC2, HDAC3, HDAC10).